In EDS ansehen

Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients

Gespeichert in:
Bibliographische Detailangaben
Titel: Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients
Autoren: Feder, Susanne, Haberl, Elisabeth M., Spirk, Marlen, Weiss, Thomas S., Wiest, Reiner, Büchler, Christa
Quelle: Clin Exp Med
Feder, Susanne; Haberl, Elisabeth M; Spirk, Marlen; Weiss, Thomas S; Wiest, Reiner; Buechler, Christa (2020). Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients. Clinical and experimental medicine, 20(2), pp. 289-297. 10.1007/s10238-020-00617-4 <http://dx.doi.org/10.1007/s10238-020-00617-4>
Verlagsinformationen: Springer Science and Business Media LLC, 2020.
Publikationsjahr: 2020
Schlagwörter: Adult, Aged, 80 and over, Liver Cirrhosis, Male, 0301 basic medicine, ddc:610, 0303 health sciences, Carcinoma, Hepatocellular, Liver Neoplasms, 610 Medizin, 610 Medicine & health, Hepatic Veins, Middle Aged, MELD score · Ascites · Prothrombin time · Varices · Liver cancer, 3. Good health, Carcinoma, Hepatocellular/etiology [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Ascites, Original Article, Liver Neoplasms/pathology [MeSH], Liver Cirrhosis/etiology [MeSH], Male [MeSH], Serum Amyloid P-Component/analysis [MeSH], Liver cancer, Liver Function Tests [MeSH], Prothrombin time, Carcinoma, Hepatocellular/blood [MeSH], Female [MeSH], Hepatic Veins/metabolism [MeSH], Adult [MeSH], Varices, Biomarkers/blood [MeSH], Humans [MeSH], Liver Cirrhosis/blood [MeSH], Carcinoma, Hepatocellular/pathology [MeSH], Middle Aged [MeSH], Liver Neoplasms/blood [MeSH], C-Reactive Protein/analysis [MeSH], MELD score, Liver Neoplasms/etiology [MeSH], Serum Amyloid P-Component, 03 medical and health sciences, C-Reactive Protein, Liver Function Tests, Humans, Female, Biomarkers, Aged
Beschreibung: The acute-phase protein pentraxin-3 (PTX3) is a component of the innate immune system. Inflammation and tissue injury increased PTX3 in the injured liver, and accordingly, circulating PTX3 was induced in patients with chronic liver diseases. In the present study, PTX3 protein was determined in systemic, hepatic, and portal vein plasma of patients with liver cirrhosis to assess a possible association between hepatic PTX3 release and extent of liver injury. However, PTX3 levels were not related to disease severity. Of note, portal PTX3 levels were higher than concentrations in the hepatic vein. PTX3 in the hepatic and portal veins was negatively correlated with factor V, antithrombin 3, and prothrombin time. PTX3 did neither correlate with C-reactive protein nor galectin-3 or resistin, whereby the latter two proteins are associated with hepatic injury. PTX3 levels were not changed in cirrhosis patients with ascites or varices and did not correlate with the hepatic venous pressure gradient. Likewise, serum PTX3 was not correlated with histological steatosis, inflammation, or fibrosis stage in patients with hepatocellular carcinoma (HCC). Moreover, PTX3 was not associated with tumor node metastasis classification in HCC. Above all, PTX3 increased in hepatic, portal, and systemic blood immediately after transjugular intrahepatic portosystemic shunt (TIPS). Higher PTX3 in portal than hepatic vein plasma and further increase after TIPS suggests that the liver eliminates PTX3 from the circulation. In summary, PTX3 is not of diagnostic value in cirrhosis and HCC patients.
Publikationsart: Article
Other literature type
Dateibeschreibung: application/pdf
Sprache: English
ISSN: 1591-9528
1591-8890
DOI: 10.1007/s10238-020-00617-4
DOI: 10.7892/boris.148449
DOI: 10.5283/epub.44791
DOI: 10.1007/s10238-020-00617-410.5283/epub.44791
Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s10238-020-00617-4.pdf
https://pubmed.ncbi.nlm.nih.gov/32078718
https://link.springer.com/article/10.1007/s10238-020-00617-4
https://pubmed.ncbi.nlm.nih.gov/32078718/
https://epub.uni-regensburg.de/44791/
https://www.ncbi.nlm.nih.gov/pubmed/32078718
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181432
https://boris.unibe.ch/148449/
https://repository.publisso.de/resource/frl:6470632
https://epub.uni-regensburg.de/44791/
Rights: CC BY
Dokumentencode: edsair.doi.dedup.....80c98e39d1bb55d73ff3f6b17a9b66f8
Datenbank: OpenAIRE
Beschreibung
Abstract:The acute-phase protein pentraxin-3 (PTX3) is a component of the innate immune system. Inflammation and tissue injury increased PTX3 in the injured liver, and accordingly, circulating PTX3 was induced in patients with chronic liver diseases. In the present study, PTX3 protein was determined in systemic, hepatic, and portal vein plasma of patients with liver cirrhosis to assess a possible association between hepatic PTX3 release and extent of liver injury. However, PTX3 levels were not related to disease severity. Of note, portal PTX3 levels were higher than concentrations in the hepatic vein. PTX3 in the hepatic and portal veins was negatively correlated with factor V, antithrombin 3, and prothrombin time. PTX3 did neither correlate with C-reactive protein nor galectin-3 or resistin, whereby the latter two proteins are associated with hepatic injury. PTX3 levels were not changed in cirrhosis patients with ascites or varices and did not correlate with the hepatic venous pressure gradient. Likewise, serum PTX3 was not correlated with histological steatosis, inflammation, or fibrosis stage in patients with hepatocellular carcinoma (HCC). Moreover, PTX3 was not associated with tumor node metastasis classification in HCC. Above all, PTX3 increased in hepatic, portal, and systemic blood immediately after transjugular intrahepatic portosystemic shunt (TIPS). Higher PTX3 in portal than hepatic vein plasma and further increase after TIPS suggests that the liver eliminates PTX3 from the circulation. In summary, PTX3 is not of diagnostic value in cirrhosis and HCC patients.
ISSN:15919528
15918890
DOI:10.1007/s10238-020-00617-4